Alnylam Pharmaceuticals, Inc.
ALNYNASDAQHealthcare● Active
$292.79
$-10.26(-3.39%)
Market Cap$39.1B
P/E Ratio—
52W High$495.55
52W Low$283.1
Alnylam Pharmaceuticals, Inc.（ALNY）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · ALNY · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $3.71B | $2.25B | $1.83B | $1.04B | $0.84B |
| Cost of Revenue | $0.68B | $0.32B | $0.31B | $0.17B | $0.14B |
| Gross Profit | $3.04B | $1.92B | $1.52B | $0.87B | $0.70B |
| Gross Margin %(computed) | 81.77% | 85.62% | 83.02% | 83.73% | 83.40% |
| Operating Expenses | |||||
| R&D Expenses | $1.32B | $1.13B | $1.00B | $0.88B | $0.79B |
| G&A Expenses | $0.00B | $0.98B | $0.80B | $0.77B | $0.62B |
| Total Operating Expenses | $2.54B | $2.10B | $1.80B | $1.65B | $1.41B |
| Operating Income | $0.50B | ($0.18B) | ($0.28B) | ($0.79B) | ($0.71B) |
| Operating Margin %(computed) | 13.51% | -7.87% | -15.43% | -75.68% | -83.93% |
| Interest Income | $0.11B | $0.12B | $0.10B | $0.02B | $0.00B |
| Interest Expense | $0.25B | $0.14B | $0.12B | $0.16B | $0.14B |
| Income Before Tax | $0.32B | ($0.38B) | ($0.43B) | ($1.13B) | ($0.85B) |
| Income Tax Expense | $0.01B | ($0.10B) | $0.01B | $0.00B | $0.00B |
| Net Income | $0.31B | ($0.28B) | ($0.44B) | ($1.13B) | ($0.85B) |
| Net Margin %(computed) | 8.45% | -12.37% | -24.08% | -109.04% | -101.01% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $2.39 | $-2.18 | $-3.52 | $-9.30 | $-7.20 |
| Wtd Avg Shares | 0.13B | 0.13B | 0.12B | 0.12B | 0.12B |
| EBITDA | $0.56B | ($0.18B) | ($0.26B) | ($0.93B) | ($0.66B) |
| EBITDA Margin %(computed) | 15.00% | -7.95% | -14.12% | -89.31% | -78.36% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-08 · USD · B
深入了解Alnylam Pharmaceuticals, Inc.
关于Alnylam Pharmaceuticals, Inc.（ALNY）损益表
Alnylam Pharmaceuticals, Inc.（ALNY）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，ALNY实现营收$3.71B，毛利润$3.04B（毛利率81.77%），净利润$0.31B（净利率8.45%）。
常见问题
ALNY · 4 问Alnylam Pharmaceuticals, Inc.（ALNY）2025财年营收为$3.71B，同比up65.2%。
ALNY revenueALNY salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08